ABSTRACT

High performance liquid chromatography is at present one of the most sophisticated tool of the

analysis. The estimation of Sumatriptan and Naproxen was done by RP-HPLC. The Phosphate

buffer was pH 3.0 and the mobile phase was optimized with consists of Methanol: Phosphate buffer

mixed in the ratio of 70:30 % v/ v. Inertsil C18 column C18 (4.6 x 150mm, 5m) or equivalent

chemically bonded to porous silica particles was used as stationary phase. The detection was carried

out using UV detector at 260 nm.

KEY WORDS: Methanol: Phosphate buffer, Inertsil C18 column, Sumatriptan and Naproxen
INTRODUCTION

1.1. INTRODUCTION TO ANALYTICAL CHEMISTRY

Analytical chemistry is often described as the area of chemistry responsible for characterizing the
composition of matter, both qualitatively (what is present) and quantitatively (how much is present).
Analytical chemistry is not a separate branch of chemistry, but simply the application of chemical
knowledge.
1.2. PHARMACEUTICAL AN ALYSIS

Pharmaceutical Analysis is the b ranch of chemistry involved in separating, identifying and

determining the relative amounts of the components making up a sample of matter. It is mainly
involved in the qualitative identi fication or detection of compounds and quantitative
measurements of the substances present in bulk and pharmaceutical preparation.

1.3. INTRODUCTION TO CH ROMATOGRAPHY

Chromatography was originally developed by the Russian botanist M ichael Tswett in 1903
for the separation of col ored plant pigments by percolating a petrole um ether extract through a
glass column packed w ith powdered calcium carbonate.
 2.LITERATURE REVIEW
2.1. Nalluri ., The present paper describes a sensitive and simple RP-HPLC-PDA method
for the simultaneous estimation of Naproxen Sodium (NPX) and Diphenhydramine
Hydrochloride (DPH) in the presence of their degradants. The drugs were subjected to stress
conditions (forced degradation) to show the stability-indicating power of the method.

2.2Namrata Parikh ., The analytical wavelengths selected for quantification were 247.4nm
for NPS (zero crossing point for DPH) and 266nm for DPH (zero crossing point for NPS).
Dual wavelength method was also developed for simultaneous estimation of DPH and NPS
in combined dosage form.

2.3R.P. Bhole ., The separation was carried out on aluminum plates precoated with silica gel

60 F254 using mobile phase toluene:methanol:glacial acetic acid (7.5:1:0.2, v/v/v). The
linearity range lies between 200 and 1200 ng/band for DPH and 1760 and 10,560 ng/band
for NPS with correlation coefficients of 0.994 and 0.995, respectively.

2.4. Mokhtar ., The HPLC method involves separation of naproxen and diphenhydramine
on XBridgeTMC18 reversed phase (4.6×150 mm, particle size 5µm) column using a mobile
phase consists of ethanol: phosphate buffer; pH 3in a ratio of 60:40 (v/v). The flow rate was
1 mL.min-1with ultraviolet detection at 216 nm.
 AIM AND OBJECTIVE
The literature review reveals the few HPLC methods for the estimation of
Sumatriptan and naproxen and in combination with other drugs. Few methods are also reported for
estimation of both drugs from formulation .we intends to develop a RP-HPLC method by
simultaneous determination with simple, rapid, greater sensitivity and faster elution.

OBJECTIVE:

1. Development of a HPLC method for analysis of bot

2. Validation of the method using formulations.
h the drugs.
 PLAN OF WORK
To develop a new analytical method for the simultaneous estimation of Sumatriptan and

Naproxen by RP-HPLC.

Selection Of Drug

Selection of λ max
Literature Review
 Selection of column
Analytical Method Development Selection of
mobile phase

Selection of flow rate

Analytical Method Validation

Optimized chromatographic
condition

DRUG PROFILE

S UMATRIPTAN SUCCINATE
Chemical formula : C 14H 21 N 3O 2S

Molecular weight : 295.40 2 g/mol

Category : H1-an tihistamine

.GENERIC NAME : sumatriptan

BRAND NAME : Act su matriptam

NAPROXEN

: C14H14O3

Chemical formula

Category : Ag onist at mu, kappa, delta, opioid receptors

GENERIC NAME : naproxen

BRAND NAME : Alev e, Naprosyn, Anaprox

Table no.8 List of marketed formulations

Brand
SI.No Drug -1 (mg) Drug-2(mg) Manufac turer
name

S umatriptan Naproxen Glaxosmithkline

1 Treximet
85mg 500mg pharmaceu ticals
 EXPERIMENTAL METHODOLOGY

INSTRUMENTS USED
T.6.1: Instruments used
SL.No Instrument Model

1 HPLC WATERS, software:Empower, 2695

separation module,PDA detector.
+
2 UV/VIS spectrophotometer LABINDIA UV 3000
3 pH meter Adwa – AD 1020

4 Weighing machine Afcoset ER-200A

5 Pipettes and Burettes Borosil

6 Beakers Borosil

6.2: CHEMICALS USED:

T. 5.2: Chemicals used

SL.No Chemical Brand

1 Sumatriptan Mylon

2 Naproxen Cipla

3 KH2PO4 FINER chemical LTD

4 Water and Methanol for HPLC LICHROSOLV (MERCK)

5 Acetonitrile for HPLC MOLYCHEM

6 Ortho phosphoric Acid MERCK

 6.3: HPLC METHOD DEVELOPMENT:

6.3.1: Mobile Phase Optimization:

Initially the mobile phase tried was methanol: Ammonium acetate buffer and Methanol:
phosphate buffer with various combinations of pH as well as varying proportions. Finally, the
mobile phase was optimized to potassium dihydrogen phosphate with buffer (pH 3.0),
Methanol in proportion 30: 70 v/v respectively.
6.3.2: Wave length selection:
UV spectrum of 10 µg / ml Sumatriptan and Naproxen in diluents (mobile phase
composition) was recorded by scanning in the range of 200nm to 400nm. From the UV spectrum
wavelength selected as 260.
6.3.3. Optimization of Column:
The method was performed with various columns like C18 column, hypersil column,
lichrosorb, and inertsil ODS column. Inertsil ODS (4.6 x 150mm, 5m) was found to be ideal as
it gave good peak shape and resolution at 0.8ml/min flow.

6.4. OPTIMIZED CHROMATOGRAPHIC CONDITIONS:

Instrument used : Waters HPLC with auto sampler and PAD or detector.
Temperature : Ambient
Column : Inertsil ODS (4.6 x 150mm, 5m)
Buffer : 6.8 grams of potassium dihydrogen ortho phosphate in
1000 ml water pH adjusted with ortho phaosparic acid.
pH : 3.0
Mobile phase : 30% buffer 70% Methanol
Flow rate : 0.8 ml per min
Wavelength : 260 nm
Injection volume : 10 l
Run time : 10min.
6.5: PREPARATION OF BUFFER AND MOBILE PHASE:
6.5.1: Preparation of Phosphate buffer:
 Accurately weighed 6.8 grams of KH2PO4 was taken in a 1000ml volumetric flask,
dissolved and diluted to 1000ml with HPLC water and the volume was adjusted to pH 3.0 with
Orthophosphoric acid.

6.5.2 Preparation of mobile phase:

Accurately measured 300 ml (30%) of above buffer and 700 ml of Methanol HPLC
(70%) were mixed and degassed in an ultrasonic water bath for 10 minutes and then filtered
through 0.45 µ filter under vacuum filtration.
6.5.3 Diluent Preparation:
The Mobile phase was used as the diluent.

6.6 PREPARATION OF THE SUMATRIPTAN & NAPROXEN

STANDARD & SAMPLE SOLUTION:

6.6.1 Standard Solution Preparation:

Accurately weigh and transfer 10 mg of Sumatriptan and Naproxen 10mg of working standard
into a 10mL& 100ml clean dry volumetric flask add about 7mL of Diluent and sonicate to
dissolve it completely and make volume up to the mark with the same solvent.
6.6.2 Sample Solution Preparation:
Accurately weigh 10 tablets crush in mortor and pestle and transfer equivalent to
10 mg of Sumatriptan and Naproxen (marketed formulation) sample into a 10mL clean dry
volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely and make
volume up to the mark with the same solvent.

6.6.3. Procedure:
Inject 20 L of the standard, sample into the chromatographic system and measure the areas for
Sumatriptan and Naproxen peaks and calculate the %Assay by using the formulae.
6.7. SYSTEM SUITABILITY:

Tailing factor for the peaks due to Sumatriptan and Naproxen in Standard solution
Should not be more than 2.0
Theoretical plates for the Sumatriptan and Naproxen peaks in Standard solution should not be
less than 2000.
6.8.METHOD VALIDATION SUMMARY:

6.8.1.PRECISION:

Preparation of stock solution:

Accurately weigh and transfer 25 mg of Sumatriptan and Naproxen working standard into a
10mL clean dry volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely
and make volume up to the mark with the same solvent.
6.8.1 INTERMEDIATE PRECISION/RUGGEDNESS:

To evaluate the intermediate precision (also known as Ruggedness) of the method,

Precision was performed on different day by using different make column of same dimensions.
Preparation of stock solution:
Accurately weigh and transfer 25 mg of Sumatriptan and 10mg of Naproxen working
standard into a 10mL clean dry volumetric flask add about 7mL of Diluent and sonicate to
dissolve it completely and make volume up to the mark with the same solvent.
6.8.1 ACCURACY:
Preparation of Standard stock solution:
Accurately weigh and transfer 10 mg of Sumatriptan and Naproxen 10mg of working standard
into a 10mL& 100ml clean dry volumetric flask add about 7mL of Diluent and sonicate to
dissolve it completely and make volume up to the mark with the same solvent.
Preparation Sample solutions:
For preparation of 50% solution (With respect to target Assay concentration):
Accurately weigh and transfer 5mg of Sumatriptan and 5.3mg of Naproxen
working standard into a 10mL and 100 ml 0f clean dry volumetric flask add about 7mL of
Diluent and sonicate to dissolve it completely and make volume up to the mark with the same
solvent.
For preparation of 100% solution (With respect to target Assay concentration):
Accurately weigh and transfer 10 mg of Sumatriptan and 10 mg of Naproxen working
standard into a 10mL and 100 ml 0f clean dry volumetric flask add about 7mL of Diluent and
sonicate to dissolve it completely and make volume up to the mark with the same solvent.
For preparation of 150% solution (With respect to target Assay concentration):
Accurately weigh and transfer 14.4mg of Sumatriptan and 14.5mg of Naproxen working
standards into a 10mL and 100ml of clean dry volumetric flask add about 7mL of Diluent and
sonicate to dissolve it completely and make volume up to the mark with the same solvent.
Procedure:
Inject the standard solution, Accuracy -50%, Accuracy -100% and Accuracy
-150% solutions.

Acceptance Criteria:
 The % Recovery for each level should be between 98.0 to 102.0%.

6.8.1 LINEARITY:
Preparation of stock solution:
Accurately weigh 10 tablets crush in mortor and pestle and transfer equivalent to 10 mg of
Sumatriptan and Naproxen (marketed formulation) sample into a 10mL clean dry volumetric
flask add about 7mL of Diluent and sonicate to dissolve it completely and make volume up to the
mark with the same solvent.
Preparations of Level – I (100ppm of Sumatriptan &1ppm of Naproxen ):
1ml and 0.1 ml of stock solutions has taken in different 10ml of volumetric flasks, dilute up to
the mark with diluent.
Preparations of Level – II (200ppm of Sumatriptan &2ppm of Naproxen ):
2ml and 0.2 ml of stock solutions has taken in different 10ml of volumetric flasks, dilute up to
the mark with diluent.
Preparations of Level – III (300ppm of Sumatriptan &3ppm of Naproxen ):
3ml and 0.3 ml of stock solutions has taken in different 10ml of volumetric flasks, dilute up to
the mark with diluent.
Preparations of Level – IV (400ppm of Sumatriptan &4ppm of Naproxen ):
4ml and 0.4 ml of stock solutions has taken in different 10ml of volumetric flasks, dilute up to
the mark with diluent
Preparations of Level – V (500ppm of Sumatriptan &5ppm of Naproxen )
5ml and 0.5 ml of stock solutions has taken in different 10ml of volumetric flasks, dilute up to
the mark with diluent
Procedure:
Inject each level into the chromatographic system and measure the peak area.
Acceptance Criteria:
 Correlation coefficient should be not less than 0.999.

6.8.5 LIMIT OF DETECTION:

6.8.5.1. Limit of Detection: (For Sumatriptan):

Preparation of 300µg/ml solution:
Accurately weigh and transfer 10 mg of Sumatriptan working standard into a 10mL clean
dry volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely and make
volume up to the mark with the same solvent.

Preparation of 0.12µg/ml solution):

Further pipette 1ml of the above stock solution into a 10ml volumetric flask and dilute up to
the mark with diluent.
Further pipette 1ml of the above stock solution into a 10ml volumetric flask and dilute up to
the mark with diluent
Pipette 0.4mL of 1µg/ml solution into a 10 ml of volumetric flask and dilute up to the mark
with diluent.
6.8.5.2. Limit Of Detection: (For Naproxen )
Preparation of 3µg/ml solution:
Accurately weigh and transfer 10mg of Naproxen working standard into a 100ml clean
dry volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely and make
volume up to the mark with the same solvent.
Preparation of 0.015µg/ml solution):
Further pipette 1ml of the above stock solution into a 10ml volumetric flask and dilute up
to the mark with diluent.
Further pipette 0.5ml of the above stock solution into a 10ml volumetric flask and dilute up to
the mark with diluent.

6.8.6 LIMIT OF QUANTIFICATION:

6.8.6.1 Limit Of Quantification (for Sumatriptan
Preparation of 300µg/ml solution:
Accurately weigh and transfer 10 mg of Sumatriptan working standard into a 10mL clean
dry volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely and make
volume up to the mark with the same solvent.

Preparation of 0.42µg/ml solut ion):

Further pipette 1ml of the above stock solution into a 10ml volumetric flask and dilute up to the
mark with diluent.
Pipette 1.0mL of above solution into a 10 ml of volumetric flask and dilute up to the mark with
diluent.
Pipette 1.4 mL of above solution into a 10 ml of volumetric flask and dilute up to the mark with
diluent.

Acceptance Criteria:
 S/N Ratio value shall be 10 for LOQ solution.
6.8.6.2 Limit Of Quantification:((for Naproxen )
Preparation of 3µg/ml solution:
Accurately weigh and transfer 10mg of Naproxen working standard into a 100mL clean dry
volumetric flask add about 7mL of Diluent and sonicate to dissolve it completely and make
volume up to the mark with the same solvent.
Preparation of 0.05µg/ml solution):
Further pipette 1ml of the above stock solution into a 10ml volumetric flask and dilute
up to the mark with diluent.
Pipette 1.7mL of above solution into a 10 ml of volumetric flask and dilute up to the mark with
diluent.

6.9 ROBUSTNESS:
As part of the Robustness, deliberate change in the Flow rate, Mobile Phase composition,
Temperature Variation was made to evaluate the impact on the method.

a). The Organic composition in the Mobile phase was varied from 50% to 50%.
Standard solution 300 µg/ml of Sumatriptan & 3µg/ml of Naproxen was prepared and
analysed using the varied Mobile phase composition along with the actual mobile phase
composition in the method.
 RESULTS AND DISCUSSION

OPTIMIZED CHROMATOGRAM IS OBTAINED BY FOLLOWING CONDITIONS:

Trial 1:
Mp : Water: Methan (50:50%v/v)
Column : Xterra C18.1 (4.6*250mm) 5µm
Fl : 1.0 ml/min
Wl : 260 nm
Ct : Ambient
St : Ambient
Iv : 10 µl

7.1(a) Trial chromatogram for Sumatriptan and naproxen

Trial 2:
Mp : Phospha buff (0.05m) pH 4.0: Methan (40:60%v/v)
Column : Make; Xterra C18.1 (4.6*250mm) 5µm
Fr : 1.0 ml/min
Wl : 260 nm
Ct : Ambient
St : Ambient
Iv : 10 µl
 7.1(b) Trial chromatogram for Sumatriptan and naproxen

Trial 3:
Mp : Phospha buff (0.05m) pH 4.0: Methan (40:60%v/v)
Column : Symmetry C18.1 5µm (4.6*250mm) Make; waters
Fr : 0.8 ml/min
Wl : 260 nm
Ct : Ambient
Sp : Ambient
Iv : 10 µl

7.1(c) Trial chromatogram for Sumatriptan and naproxen

Trial 4:
Mp : Phospha buffe (0.05M) pH 3.6: ACN (40:60%v/v)
Column : Symmetry C18.1 5µm (4.6*250mm) Make; waters
Fr : 0.8 ml/min
Wl : 260 nm
Ct : Ambient
St : Ambient
Iv : 20 µl

7.1(d) Trial chromatogram for Sumatriptan and naproxen

Trial 5:
Mp : Phospha buff pH 3.0: Methanol (30:70%v/v)
Column : Inertsil C18.1 5µm (4.6*25 0mm)
Fr : 0.8 ml/min
Wl : 260 nm
Ct : Ambient
St : Ambient
Iv : 10 µl
 7.1(e) Trial chromatogram for Sumatriptan and naproxen
Chromatogram for Sumatriptan and naproxen
Column : Inertsil C18.1 (4.6 x 250mm, 5m)
Buffe pH : 3.0.
Mp : 30% buff 70% Methano
Fr : 1.0ml per min
Wl : 260 nm
Temperature : ambient.
Rt

Figure 7.1(h) chromatogram for blank

From the above chromatogram it was observed that there are no interferences.
 7.1(g) Chromatogram for Sumatriptan and naproxen sample Preparation
From the above chromatogram it was observed that the Sumatriptan and naproxen peaks are
well separated
Retention time of Sumatriptan – 2.669min
Retention time of naproxen - 3.855 min.

7.1(h) Chromatogram for Sumatriptan and naproxen Standard Preparation

Retention time of Sumatriptan – 2.569 min

Retention time of naproxen - 3.842 min.
 7.2: SYSTEM SUITABILITY:

F.7.2 chromatogram for system suitability

T.1: Results of system suitability parameters for Sumatriptan and naproxen

S.No Name Retention Area Height USP USP USP plate

time(min) (µV sec) (µV) resolution tailing count

1 Sumatriptan 2.5 124505 213642 1.2 4673.4

2 naproxen 3.9 1308495 154566 60 1.3 6090.3

Acceptance criteria:
 Resolution between two drugs must be not less than 2
 Theoretical plates must be not less than 2000
 Tailing factor must be not less than 0.9 and not more than 2.
 It was found from above data that all the system suitability parameters for developed method
were within the limit.
7.3: VALIDATION PARAMETERS:
7.3.1: PRECISION:
Precision of the method was carried out for standard solutions as described under experimental
work.
F.7.3.1 (a) chromatogram for standard injection -1

F.7.3.1(b) chromatogram for standard injection-2

F.7.3.1 (c) chromatogram for standard injection-3

F.7.3.1 (d) chromatogram for standard injection-4

F.7.3.1 (e) chromatogram for standard injection-5

T. 2: Results of method precession for Sumatriptan :

Injection Area

Injection-1 1302729

Injection-2 1302947

Injection-3 1303236
Injection-4 1303977
Injection-5 1309759
 Average 1304529.8
Standard Deviation 2961.1
%RSD 0.2

T. 3: Results of method precession for naproxen:

Injection Area

Injection-1 123149

Injection-2 123766

Injection-3 124271

Injection-4 124691

Injection-5 124956

Average 124162.7
Standard Deviation 725.6

%RSD 0.6

Acceptance criteria:
 %RSD for sample should be NMT 2
 The %RSD for the standard solution is below 1, which is within the limits hence method is
precise.

7.3.2. INTERMEDIATE PRECESSION (RUGGEDNESS):

There was no significant change in assay content and system suitability parameters at different
conditions of ruggedness like day to day and system to system variation.

F.7.3.2 (a) chromatogram for sample injectiocn-1

F. 7.3.2 (b) chromatogram for sample injection-2

F. 7.3.2 (c) chromatogram for sample injection-3

 F.7.3.2 (d) chromatogram for sample injection-4

F. 7.3.2 (e) chromatogram for sample injection-5

T. 5: Results of Intermediate precision for Sumatriptan

Injection Area

Injection-1 1300148

Injection-2 1304520
 Injection-3 1305937

Injection-4 1306476

Injection-5 130871

Average 1305070.2
Standard Deviation 3061.8

%RSD 0.2

T. 5: Results of Intermediate precision for naproxen

Injection Area

Injection-1 122487

Injection-2 122626

Injection-3 122632

Injection-4 122702

Injection-5 122962

Average 122681.8
Standard Deviation 174.8

%RSD 0.1

Acceptance criteria:
 %RSD of five different sample solutions should not more than 2
 The %RSD obtained is within the limit, hence the method is rugged.
7.3.3: ACCURACY:
Sample solutions at different concentrations (50%, 100%, and 150%) were prepared and the %
recovery was calculated.
7.3.3.1. Chromatograms For Sample Concentration-50%:

F.7.3.3.1 (a) chromatogram for sample concentration-50%

F.7.3.3.1 (b) chromatogram for sample concentration-50%

 F.7.3.3.1 (c) chromatogram for sample concentration-50%

7.3.3.2. Chromatograms For Sample Concentration-100%:

F.7.3.3.2 (a) chromatogram for sample concentration-100%

 F.7.3.3.2 (b) chromatogram for sample concentration-100%

F.7.3.3.2 (c) chromatogram for sample concentration-100%

7.3.3.3. Chromatograms For Sample Concentration-150%:

F.7.3.3.3 (a) chromatogram for sample concentration-150%

 F.7.3.3.3 (b) chromatogram for sample concentration-150%

F.7.3.3.3 (c) chromatogram for sample concentration-150%

T.-6 accuracy (recovery) data for Sumatriptan

%Concentration Amount Amount

Mean
(at specification Area Added Found % Recovery
Recovery
Level) (mg) (mg)

50% 656659.5 5.0 5.036 100.7% 99.84%

 100% 1304258 10.0 10.003 100.0%

150% 1854608 14.4 14.224 98.780%

T.-7 accuracy (recovery) data for naproxen

%Concentration Amount Amount

Mean
(at specification Area Added Found % Recovery
Recovery
Level) (mg) (mg)

50% 65800 5.3 5.34 100.8%

100% 124353 10 10.10 100.01% 100.51%

150% 177940 14.2 14.45 99.68%

Acceptance Criteria:
 The % Recovery for each level should be between 98.0 to 102.0%.
 The percentage recovery was found to be within the limit (97-103%).
The results obtained for recovery at 50%, 100%, 150% are within the limits. Hence method is
accurate

3.4 LINEARITY:
The linearity range was found to lie from 100µg/ml to 50 0µg/ml of Sumatriptan ,
5µg/ml to 25µg/ml 0f naproxen and chromatograms are shown below.
F.7.3.4 (a) chromatogram for linearity concentration-100µg/ml of Sumatriptan & 5 µg/ml
of naproxen

F.7.3.4 (b) chromatogram for linearity concentration-200 µg/ml of Sumatriptan & 10 µg/ml
of naproxen
 F.7.3.4 (c) chromatogram for linearity concentration--300 µg/ml of
Sumatriptan & 15 µg/ml of naproxen

sass

F.7.3.4 (d) chromatogram for linearity concentration-400ppm of Sumatriptan & 20ppm of

naproxen
F.7.3.4 (e) chromatogram for linearity concentration-500 µg/ml of Sumatriptan & 25 µg/ml
of naproxen

T.-8 Area of different concentration of Sumatriptan

S.No. Linearity Level Concentration Area

1 I 100ppm 668934

2 II 200ppm 956781

3 III 300ppm 1313873

4 IV 400ppm 1563458
5 V 500ppm 1867084

Correlation Coefficient 0.999

T.-9 Area of different concentration of naproxen

S.No Linearity Level Concentration Area

1 I 1ppm 66510

94701
2 II 2ppm

3 III 3ppm 124802

152731
4 IV 4ppm

179732
5 V 5ppm

Correlation Coefficient 0.999

F. 7.3.4 (f) calibration graph for Sumatriptan at 225 nm
 .7.3.4 (f) calibration graph for naproxen at 225 nm

T.-9 Analytical performance parameters of Sumatriptan and naproxen???

Parameters Sumatriptan Naloxone

Slope (m) 66574 12529
Intercept (c) 53592 50245
2
Correlation coefficient (R ) 0.999 0.999

Acceptance criteria:
2
Correlation coefficient (R ) should not be less than 0.999
 The correlation coefficient obtained was 0.999 which is in the acceptance limit. The linearity was
established in the range of 10% to 50% of Sumatriptan and 5% to 25% of naproxen.

7.3.5: LIMIT OF DETECTION FOR SUMATRIPTAN AND NAPROXEN

The lowest concentration of the sample was prepared with respect to the base line noise and
measured the signal to noise ratio
 F.7.3.5 chromatogram of Sumatriptan & naproxen showing LOD

T.-10 Results of LOD

Drug name Baseline noise(µV) Signal obtained S/N ratio

(µV)
Sumatriptan 52 152 2.9

naproxen 52 156 3

 Signal to noise ratio shall be 3 for LOD solution

 The result obtained is within the limit.

7.3.6: LIMIT OF QUANTIFICATION (LOQ):

The lowest concentration of the sample was prepared with respect to the base line noise and
measured the signal to noise ratio.
 F.7.3.6 (a) chromatogram of Sumatriptan & naproxen showing LOQ

T.-11 Results of LOQ

Drug name Baseline noise(µV) Signal obtained S/N ratio

(µV)
Sumatriptan 52 522 10.03

naproxen 52 524 10.1

 Signal to noise ratio shall be 10 for LOQ solution

 The result obtained is within the limit.

7.3.7: ROBUSTNESS:
The standard and samples of Sumatriptan and naproxen were injected by changing the conditions
of chromatography.
7.3.7.1: Variation In Flow
F.7.3.7.1 (a) chromatogram snowing less flow of 0.6ml/min

F.7.3.7.1 (b) chromatogram snowing more flow of 1.0ml/min

System Suitability Results

Flow Rate
USP Plate Count USP Tailing
S. No (ml/min)

1 0.6 5339.9 1.4

2 0.8 4673.4 1.3
3 1.0 5216.0 1.4

T.-12 Flow Rate (ml/min) data for Sumatriptan

T.-13 flow rate (ml/min) data for naproxen

System Suitability Results

Flow Rate
USP Plate Count USP Tailing
S. No (ml/min)
1 0.8 7063.3 1.3
2 1.0 6090.3 1.2
3 1.2 6998.0 1.3

7.3.7.2 Variation Of Mobile Phase Organic Composition:

F.7.3.7.2 (a) chromatogram showing less organic composition

 F.7.3.7.2 (b) chromatogram showing more organic composition

T. -14 Change in Organic Composition in the Mobile Phase for Sumatriptan

Change in Organic System Suitability Results

S.No Composition in the
USP Plate Count USP Tailing
Change in Organic
Mobile Phase System Suitability Results
S.No Composition in the
1 10% less USP Plate Count
4508.4 USP Tailing
1.3
Mobile Phase
2 *Actual 4673.4 1.4
1.2
13 10% lessmore
10% 6387.74318.1 1.3

*Actual 6090.3 1.2

2 T.
-14
Change in Organic Composition in the Mobile Phase for naproxen

Acceptance criteria:
Percentage RSD
 8. SUMMARY AND CONCLUSION

High performance liquid chromatography is at present one of the most sophisticated tool of the
analysis. The estimation of Sumatriptan and Naproxen was done by RP-HPLC. The Phosphate
H
buffer was p 3.0 and the mobile phase was optimized with consists of Methanol: Phosphate

buffer mixed in the ratio of 70:30 % v/ v. Inertsil C 18 column C18 (4.6 x 150mm, 5m) or
equivalent chemically bonded to porous silica particles was used as stationary phase. The
detection was carried out using UV detector at 260 nm.
 BIBLIOGRAPHY

1. Nalluri B. N., Mrudula B., Chitralatha K., Sultana S. A. and Chandra T. U , development of
stability indicating rp-hplc-pda method for the simultaneous analysis of naproxen sodium
and in bulk and tablet dosage forms
2. Namrata Parikh1 , Drashti P. Pradhan , Suddhasattya Dey , U. M.Upadhyay , Analytical
Method Development and Validation for Simultaneous Estimation of Diphenhydramine and
Naproxen Sodium in its Combined Dosage Form , 2016 Vol.:5, Issue:2
3. R.P. Bhole, S.S. Shinde, , A High-Performance Thin Layer Chromatography (HPTLC)
Method for Simultaneous Determination of and Naproxen Sodium in Tablets . 2015; 10: 47–
51.
4. Mokhtar M. Mabrouk, Sherin F. Hammad, Fotouh R. Mansour and Basma Z El-Khateeb ,
Simultaneous determination of naproxen and diphenhydramine by reversed phase liquid
chromatography and derivative spectrophotometry , 2015, 7(12):181-192

1.